CORRECTING and REPLACING SpeeDx and Cepheid Announce Test Partnership
First sentence, seventh paragraph of release dated April 16, 2019 should read: “Currently, there is no FDA-cleared molecular diagnostic test for the combined detection of M. genitalium and macrolide resistance markers in the U.S. Cure rates for M.genitalium have been shown to be in decline in recent studies; however, a groundbreaking paper using ResistancePlus MG as part of a Resistance Guided Therapy protocol reported significant increases in cure rates to over 92%.4”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190415005919/en/
ResistancePlus MG will be the first assay available through the Cepheid FleXible for GeneXpert program.
The corrected release reads:
SPEEDX AND CEPHEID ANNOUNCE TEST PARTNERSHIP
SpeeDx tests will be available through Cepheid’s FleXible Cartridge programme for the GeneXpert System
SpeeDx Pty, Ltd. announced an agreement with Cepheid to manufacture their market-leading ResistancePlus ® tests for use on the GeneXpert System. The first test in Cepheid’s FleXible Cartridge programme, planned for launch early 2019, is ResistancePlus ® MG, detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance.
“The availability of ResistancePlus MG in a FleXible cartridge that runs on the GeneXpert System is a compelling and exciting extension for us,” said Colin Denver, CEO of SpeeDx. “Patients are already benefiting from Resistance Guided Therapy with our central lab tests. Now clinicians can receive resistance information even faster, to support antimicrobial stewardship and more effective antibiotic treatment decisions.”
“Our new FleXible Cartridge program allows Trusted Reagent Manufacturers to develop targeted molecular tests using Cepheid’s easy-to use-cartridge.” said David H. Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. “With a global installed base of nearly 22,000 GeneXpert Systems, this technology could potentially be applied in multiple settings in which actionable treatment information is needed quickly.”
Management guidelines for Mgen infection include resistance testing1-3 in response to rising rates of macrolide resistance observed with Mgen detection-only or empiric Mgen treatment.4-6 ResistancePlus ® MG supports Mgen management guidelines and allows for Resistance Guided Therapy, which is clinically proven to improve cure rates by providing clinicians with much needed information to guide antibiotic treatment.3
About Mgen
M. genitalium can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than gonorrhea. 7 Like gonorrhea, M. genitalium is also evolving into a so-called STI superbug that is becoming resistant to many antibiotic treatments, leading to exceedingly difficult-to-treat infections and threatening global public health.8
Macrolide antibiotics, specifically azithromycin, are the first-line treatment for the rapidly growing problem of M. genitalium STIs, but resistance to these antibiotics has increased up to 50% in several countries.4-6 Due to this growing antibiotic resistance problem, several global STI Management Guidelines on Mgen Infections recommend complementing the use of molecular testing to detect M. genitalium with an assay capable of detecting macrolide resistance-associated mutations.1-3
Currently, there is no FDA-cleared molecular diagnostic test for the combined detection of M. genitalium and macrolide resistance markers in the U.S. Cure rates for M.genitalium have been shown to be in decline in recent studies; however, a groundbreaking paper using ResistancePlus MG as part of a Resistance Guided Therapy protocol reported significant increases in cure rates to over 92%.4 The SpeeDx ResistancePlus ® MG assay is CE marked for sale in Europe and TGA approved for sale in Australia. The test provides valuable detection and antibiotic resistance information to clinicians in a rapid time frame. Timely detection of antibiotic resistant infections enables Resistance Guided Therapy for better treatment of the disease for patients, lessening the potential for spreading among vulnerable populations and combating antibiotic resistance.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.
1. Jensen JS, Cusini M, Gomberg M, Moi H. 2016. 2016 European
guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol
Venereol. PMID: 27505296.
2. https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
3.
http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
4.
Read T R H, Fairley C K, Murray G L, et al. Outcomes of
resistance-guided sequential treatment of Mycoplasma genitalium
infections: a prospective evaluation, Clinical Infectious Diseases,
ciy477, https://doi.org/10.1093/cid/ciy477
5.
Getman D, Jiang A, O'Donnell M, Cohen S. 2016. Mycoplasma
genitalium prevalence, coinfection, and macrolide antibiotic resistance
frequency in a multicenter clinical study cohort in the United States. J
Clin Microbiol 54:2278-2283.
6. Murray GL, Bradshaw CS,
Bissessor M, et al. Increasing Macrolide and Fluoroquinolone
Resistance in Mycoplasma genitalium. Emerging Infectious Diseases.
2017;23(5):809-812. doi:10.3201/eid2305.161745.
7. Miller WC,
Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal
infections among young adults in the United States. JAMA 2004;
291:2229–2236.
8. Unemo, M. & Jensen, J.S.
‘Antimicrobial-resistant sexually transmitted infections: gonorrhoea and
Mycoplasma genitalium’. 2016. Nat. Rev. Urol.268. Published online 10
Jan 2017. doi:10.1038/nrurol
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190415005919/en/
Contact information
SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61
2 9209 4170
madelineo@speedx.com.au
USA:
Rick
Roose
+1 415.202.4445
roi.roose@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Results of the MSCI 2025 Market Classification Review25.6.2025 00:55:00 EEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 23:15:00 EEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
NetApp Appoints Disruptive Innovator Syam Nair as Chief Product Officer, Underscoring its Commitment to Bold Product Vision24.6.2025 23:05:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Syam Nair as its new Chief Product Officer (CPO), effective Monday, July 7, 2025. Nair succeeds Harv Bhela, who concluded his tenure in June following a successful chapter of product leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624871234/en/ Syam Nair, Chief Product Officer at NetApp Nair is a former Salesforce and Microsoft executive renowned as a maverick innovator in the industry, bringing over 25 years of experience in scaling cloud platforms and driving hyper-growth. In his new role, Nair will lead NetApp’s product and engineering teams to accelerate innovation in hybrid cloud and AI offerings and advance NetApp’s strategic vision for data-driven business growth. “I am thrilled to welcome Syam to NetApp’s leadership team. He joins us at a time when our customers are looking to NetApp to help them deli
Mirion Technologies and Westinghouse Partner to Drive Digital Innovation in Nuclear Instrumentation Systems24.6.2025 23:04:00 EEST | Press release
Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide. This initiative leverages Mirion’s proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK product line represents an advanced and reliable Ex-core neutron flux measurement solution to replace the outdated equipment that can be c
Auramet Closes $350 Million Syndicated Revolving Credit Facility to Support Metals Franchise24.6.2025 19:35:00 EEST | Press release
Auramet International, Inc. (“Auramet”), a leading precious metals merchant, is pleased to announce that it has closed a $350 million syndicated revolving credit facility (the “Facility”) led by Macquarie Group (“Macquarie”). Macquarie’s Commodities and Global Markets business acted as Mandated Lead Arranger, Bookrunner and Administrative Agent for the Facility, which was well oversubscribed. The Facility complements Auramet’s various bilateral banking facilities. Auramet welcomes the addition of Natixis, New York Branch to the bank group, joining the existing bank group that includes Coöperatieve Rabobank U.A., N.Y. Branch, HSBC Bank USA, N.A., Commonwealth Bank of Australia, Wells Fargo Bank, CIBC Bank USA, and Brown Brothers Harriman & Co. The Facility has been oversubscribed each year since inception. “Auramet’s relationships and industry knowledge are the foundation of our 21-year history and our banks have consistently provided the strong support needed for our growth,” said Kimb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom